GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

PHASE2RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions

Cerebral Small Vessel Disease

Interventions

DRUG

Exenatide extended release

2mg once weekly via subcutaneous injection

Trial Locations (1)

RECRUITING

Chinese University of Hong Kong, Hong Kong

All Listed Sponsors

lead

Chinese University of Hong Kong

OTHER